Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

The Magnitude Matters: GSK Approvals Show How To Use PFS After Other Drugs Show Survival

Nov 20 2013

• By Bridget Silverman

Related Content

FDA Will Revisit Appropriate Use Of PFS Endpoints At Advisory Committee

Sep 01 2009

<em>Avastin</em> Decision Leaves Lingering Uncertainty As To Threshold Level Of Progression-Free Survival Benefit

Nov 28 2011

<i>Avastin</i> Breast Cancer Dispute Centers On “Magnitude Of Benefit” Questions

May 30 2011

Why Survival Is The Fittest Endpoint For HRPC: The Problem With Pain

Mar 01 2011

ODAC Backs Random Sample Audits Of Progression Events

Jul 30 2012

The Next Phase In Oncology: FDA’s Pazdur Has New Vision For Drug Development

Nov 11 2013

<i>Avastin</i> Debate Could Provide Clarity On Use Of Progression-Free Survival Endpoints

Jul 11 2011

Related Companies

GSK plc

Bristol Myers Squibb Company

Roche Holding AG

Pfizer Inc.

Eli Lilly and Company

Roche Holding AG

Bristol Myers Squibb Company

Johnson & Johnson

Pharmacyclics, Inc.

Genentech, Inc.

Bayer AG

Algeta ASA

Additional Topics

Clinical Trials BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window